Latest news
Akebia Therapeutics (NASDAQ: AKBA) posts Q2 loss with $155M cash - Stock TitanStock Titan · Wed, 05 Aug 2026 20:11:44 GMTAkebia begins trial for three rare kidney diseases; data expected in 2027 - Stock TitanStock Titan · Wed, 05 Aug 2026 20:05:00 GMTCyclerion Therapeutics (NASDAQ: CYCN) outlines Korsana merger and going concern risk - Stock TitanStock Titan · Tue, 04 Aug 2026 20:16:39 GMTTwo New Akebia Hires Get Stock Options With 4-Year Vesting - Stock TitanStock Titan · Mon, 03 Aug 2026 20:05:00 GMTAkebia plans Aug. 5 webcast after markets close to discuss results - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMT